ReviewMelanoma management2019
Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.
Review in Melanoma management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Galloyl-RGD induces oxidative stress-mediated apoptosis in human melanoma cells.Molecular and cellular biochemistry · 2026Article
- Hematological Toxicities in the Modern Era of Melanoma Therapy.Journal of clinical medicine · 2026Review
- Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- A case of immunotherapy-induced thyroiditis.Exploration of targeted anti-tumor therapy · 2024Article
- Anti-tumor immunity and vitiligo: from immune-related adverse reactions to protection from cancer.Immunotherapy · 2024Article
- Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.The oncologist · 2023Article
- Immunotherapy Assessment: A New Paradigm for Radiologists.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.Journal of cancer research and clinical oncology · 2022Article
- Management of cutaneous melanoma: radiologists challenging and risk assessment.La Radiologia medica · 2022Review
- Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.Cancers · 2022Article
- Spin in Abstracts of Systematic Reviews and Meta-analyses of Melanoma Therapies: Cross-sectional Analysis.JMIR dermatology · 2022Article
- Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.International journal of molecular sciences · 2021Article
- Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature.Frontiers in neurology · 2021Article
- The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma.Frontiers in oncology · 2021Review
- Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors.Archives of dermatological research · 2021Review
- Development and Validation of an Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Checkpoint inhibitors can cause an imbalance in immune tolerance that may clinically manifest as immune-related adverse events (irAEs). These events may involve many organs and tissues, including the skin, gastrointestinal (GI) tract, liver, endocrine system, kidneys, central nervous system (CNS), eyes and lungs. The incidence of irAEs appears to be lower with anti-programmed death antigen-1/programmed death antigen-ligand-1 agents than with the anti-cytotoxic T-lymphocyte-associated protein-4 antibody ipilimumab. Combined immunotherapy does not appear to be associated with novel safety signals compared with monotherapy, but more organs may be involved. Increased experience and the use of algorithms for the most common irAEs have resulted in severe toxicity and related deaths being reduced. However, continuous vigilance, especially regarding less common events, is needed to better characterize the wide spectrum of clinical manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.